Dalvance dalbavancin: Phase III data

Next quarter, Actavis plans to submit an sNDA to FDA for the single dose regimen of IV Dalvance. The 2-dose regimen of IV Dalvance is approved to treat ABSSSIs caused by susceptible Gram-positive bact...